A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

ClinicalTrials.gov ID: NCT00282230

Public ClinicalTrials.gov record NCT00282230. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Prograf®/FK778 and Prograf®/MMF in De Novo Kidney Transplant Recipients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients

Study identification

NCT ID: NCT00282230
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Astellas Pharma Inc; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Kidney Transplantation

Interventions

FK778 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2003
Primary completion: Not listed
Completion: Sep 30, 2005
Last update posted: Jun 6, 2012

2003 – 2005

United States locations

U.S. sites: 23
U.S. states: 18
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Los Angeles	California	90057	—
Not listed	San Diego	California	92123	—
Not listed	Denver	Colorado	80262	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Miami	Florida	33136	—
Not listed	Chicago	Illinois	60637	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Wichita	Kansas	67214	—
Not listed	New Orleans	Louisiana	70121	—
Not listed	Detroit	Michigan	80262	—
Not listed	New Brunswick	New Jersey	89003	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10029	—
Not listed	Durham	North Carolina	27710	—
Not listed	Cincinnati	Ohio	45267	—
Not listed	Harrisburg	Pennsylvania	17104	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Memphis	Tennessee	38163	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Madison	Wisconsin	53792	—
Not listed	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00282230, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 6, 2012 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00282230 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →